Roche GenMark Deal – COVID-19 Makes Respiratory Segment and mPOC More Valuable
A recent deal in the news cements the viability of the respiratory segment and the use of small molecular systems to test for them. First introduced in 2013, PCR and other NAAT-based molecular systems have become a central part of testing for ailments such as flu, strep, RSV and COVID-19. They remain in competition with immunoassay systems which on the whole still field better installed base numbers. It was though antibotic resistance would be the key issue to propel these systems, but COVID-19 has proved to be the situation where they were best suited, as we had predicted when COVID-19 was not yet present in the United States last year.
As Roche has inked a $1.8 billion acquisition agreement with GenMark Diagnostics, the case for mPOC has been moved forward. The deal is expected to close in the second quarter of this year. GenMark designs molecular diagnostic tests that identify multiple pathogens from a single patient sample, Roche said. Its syndromic panel testing portfolio will complement Roche’s molecular diagnostic portfolio, according to the firm.
Kalorama’s mPOC report can be found here: https://kaloramainformation.com/product/2021-molecular-point-of-care/
Once the transaction is complete, GenMark Diagnostics will continue to operate out of its current location in Carlsbad, CA.